Aquestive Therapeutics (NASDAQ:AQST) Issues Earnings Results

Key Points

• Aquestive Therapeutics reported quarterly EPS of -$0.13, missing the consensus estimate of -$0.12, while revenue of $7.56 million fell short of the $11.02 million expected.
• Shares rose 2.9% to $3.88 in Tuesday mid-day trading despite the earnings miss.
• Analysts’ consensus rating is “Moderate Buy,” with an average price target of $8.60; insiders sold 58,750 shares worth about $271,675 over the past 90 days.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.01), FiscalAI reports. The business had revenue of $7.56 million for the quarter, compared to analysts' expectations of $11.02 million.

Aquestive Therapeutics Trading Up 2.9%

AQST stock traded up $0.11 during mid-day trading on Tuesday, hitting $3.88. The stock had a trading volume of 2,029,780 shares, compared to its average volume of 2,917,538. The firm has a market capitalization of $486.98 million, a P/E ratio of -5.97 and a beta of 1.49. Aquestive Therapeutics has a 52 week low of $2.93 and a 52 week high of $6.85. The firm has a fifty day simple moving average of $4.64 and a 200 day simple moving average of $4.20.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on AQST shares. Wall Street Zen raised Aquestive Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, September 12th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $11.00 price objective on shares of Aquestive Therapeutics in a report on Thursday, September 10th. HC Wainwright reiterated a "buy" rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Friday, October 16th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Aquestive Therapeutics in a report on Thursday, October 15th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Aquestive Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $8.60.

Insider Transactions at Aquestive Therapeutics

In related news, CEO Daniel Barber sold 25,000 shares of Aquestive Therapeutics stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $4.22, for a total transaction of $105,500.00. Following the sale, the chief executive officer directly owned 627,317 shares in the company, valued at $2,647,277.74. This trade represents a 3.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Sherry Korczynski sold 8,750 shares of the stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $5.22, for a total value of $45,675.00. Following the completion of the sale, the insider owned 235,689 shares of the company's stock, valued at $1,230,296.58. The trade was a 3.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 58,750 shares of company stock valued at $271,675. Insiders own 6.81% of the company's stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products that use its proprietary PharmFilm oral film technology. The company's films are designed to deliver medicines through the mouth, potentially offering alternatives to tablets, capsules, injections, or other conventional dosage forms.

Aquestive's marketed products include Libervant (diazepam buccal film), an FDA-approved treatment for the acute, intermittent, and stereotypic episodes of frequent seizure activity associated with epilepsy, and Exservan (riluzole oral film), an FDA-approved treatment for amyotrophic lateral sclerosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.